BRAF and metastatic melanoma: The small molecule BRAF inhibitor, encorafenib (LGX818, trade name Braftovi; Figure 1), has been approved by the FDA for the combined treatment of unresectable or metastatic melanoma harboring a BRAFV600E or -V600K mutation (in 2018), and BRAFV600E-mutant metastatic colorectal cancer (in 2020) [15,16].